The lower risk MDS patient at risk of rapid progression.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.leukres.2010.05.023PMID 20573398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

  2010cited by this paper
• p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study.

  2010cited by this paper
• Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

  2010cited by this paper
• Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

  2010cited by this paper
• Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

  2010cited by this paper
• DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

  2010cited by this paper
• Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.

  2009cited by this paper
• Accelerated cellular senescence in myelodysplastic syndrome.

  2009cited by this paper
• Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

  2009cited by this paper
• Myelodysplastic syndromes.

  2009cited by this paper
• Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD

  2009cited by this paper
• TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

  2009cited by this paper
• The changing classification of myelodysplastic syndromes: what's in a name?

  2009cited by this paper
• Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group

  2009cited by this paper
• Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.

  2009cited by this paper
• RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

  2009cited by this paper
• Myelodysplastic syndromes: biology and treatment

  2009cited by this paper
• Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

  2009cited by this paper
• The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

  2009cited by this paper
• Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia

  2009cited by this paper
• Myelodysplastic syndromes: an historical perspective.

  2008cited by this paper
• Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.

  2008cited by this paper
• International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

  2008cited by this paper
• Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

  2008cited by this paper
• WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

  2008cited by this paper
• Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.

  2008cited by this paper
• Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

  2008cited by this paper
• Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

  2008cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

  2008cited by this paper
• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  2008cited by this paper
• Consensus statement on iron overload in myelodysplastic syndromes

  2008cited by this paper
• Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?

  2008cited by this paper
• The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes.

  2008cited by this paper
• Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy

  2008cited by this paper
• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

  2007cited by this paper
• Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes

  2007cited by this paper
• Histopathology in the Diagnosis and Classification of Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myelodysplastic/Myeloproliferative Diseases

  2007cited by this paper
• Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

  2007cited by this paper
• Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

  2006cited by this paper
• Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

  2006cited by this paper
• Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

  2006cited by this paper
• Myelodysplastic syndromes in patients younger than age 50.

  2006cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• T-Cell Abnormalities in Patients with Myelodysplastic Syndromes: Improved Immunological Functions in Patients Treated with Recombinant Erythropoietin.

  2006cited by this paper
• Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

  2005cited by this paper
• Telomerase activity in myelodysplastic syndromes.

  2005cited by this paper
• The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.

  2005cited by this paper
• Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

  2005cited by this paper
• Myelodysplastic syndromes--coping with ineffective hematopoiesis.

  2005cited by this paper
• Survivin Expression in Acute Leukemias and Myelodysplastic Syndromes

  2004cited by this paper
• Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?

  2004cited by this paper
• Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia.

  2004cited by this paper
• Erythropoietin has an anti‐myeloma effect – a hypothesis based on a clinical observation supported by animal studies

  2004cited by this paper
• Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t‐AML/MDS

  2004cited by this paper
• A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

  2003cited by this paper
• Imbalance Between Apoptosis and Telomerase Activity in Myelodysplastic Syndromes: Possible Role in Ineffective Hemopoiesis

  2003cited by this paper
• Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

  2003cited by this paper
• Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

  2002cited by this paper
• Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes

  2002cited by this paper
• Telomerase activity in myelodysplastic syndrome.

  2002cited by this paper
• Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes

  2002cited by this paper
• Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

  2001cited by this paper
• Telomere Dynamics in Myelodysplastic Syndromes and Acute Leukemic Transformation

  2001cited by this paper
• Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

  2001cited by this paper
• Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

  2001cited by this paper
• Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia

  2000cited by this paper
• Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.

  1998cited by this paper
• Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997influential reference
• Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

  1997cited by this paper
• Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.

  1995cited by this paper
• Hematology: Basic Principles and Practice

  1995cited by this paper
• Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes.

  1994cited by this paper
• High la (HLA‐DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes

  1993cited by this paper
• Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders.

  1992cited by this paper
• The myelodysplastic syndromes--1990.

  1990cited by this paper
• The myelodysplastic syndromes.

  1987cited by this paper
• Bone marrow histology in myelodysplastic syndromes

  1984cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  2026cites this paper
• The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms

  2025cites this paper
• New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes.

  2025cites this paper
• The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

  2023cites this paper
• Usefulness of Genetic Aberration and Shorter Telomere Length in Myelodysplastic Syndrome: A Pilot Study.

  2022cites this paper
• Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.

  2022cites this paper
• Myelodisplastik Sendrom Tanılı Olguların Sitogenetik / Fish ve Demografik Verilerinin İncelenmesi

  2022cites this paper
• Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience

  2021cites this paper
• Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

  2020cites this paper
• Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation

  2020cites this paper
• Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.

  2019cites this paper
• Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?

  2018cites this paper
• Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts

  2018cites this paper
• Presence of CD34+ in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients

  2018cites this paper
• Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low‐risk myelodysplastic syndrome

  2018cites this paper
• The bone-marrow niche in MDS and MGUS: implications for AML and MM

  2018cites this paper
• Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome

  2017cites this paper
• Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

  2016influential citation
• The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review

  2016cites this paper
• Laboratory and clinical risk assessment to treat myelodysplatic syndromes

  2016cites this paper
• TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

  2016cites this paper
• Neutrophil to lymphocyte ratio--not an independent prognostic factor in patients with the myelodysplastic syndrome.

  2015cites this paper
• Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.

  2015influential citation
• Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

  2015cites this paper
• Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cites this paper
• Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.

  2014cites this paper
• Hematopoietic Cell Transplantation (HCT)

  2013cites this paper
• Age‐related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS

  2013cites this paper
• Telomerase gene screening and telomere overhang detection in Chinese patients with myelodysplastic syndrome.

  2013cites this paper
• A Personalized Molecular Pathogenesis of MDS

  2013cites this paper
• Beyond race-related disparities: is myelodysplastic syndrome the same everywhere?

  2013cites this paper
• Serum Ferritin Is an Independent Prognostic Factor in Chinese with Myelodysplastic Syndromes Classified as IPSS Intermediate-1

  2013cites this paper
• Prognostic models in myelodysplastic syndromes.

  2013cites this paper
• Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.

  2013cites this paper
• Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure

  2013cites this paper
• How we treat lower-risk myelodysplastic syndromes.

  2013cites this paper
• Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.

  2012cites this paper
• Current status of allogeneic hematopoietic cell transplantation for MDS.

  2012cites this paper
• Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome

  2012cites this paper
• Revisiting use of growth factors in myelodysplastic syndromes.

  2012cites this paper
• Pitfalls in bone marrow pathology: avoiding errors in bone marrow trephine biopsy diagnosis

  2011cites this paper
• ASXL1 (additional sex combs like 1 (Drosophila))

  2011cites this paper
• Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.

  2011cites this paper
• Survival benefits from reduced‐intensity conditioning in allogeneic stem cell transplantation for young lower‐risk MDS patients without significant comorbidities

  2011cites this paper